Tentative FDA approval for Lupin’s arformoterol tartrate inhalation solution and a potential EC nod for etanercept are seen aiding the company’s prospects in FY2021. Besides, success in a Phase III trial for secnidazole to treat trichomoniasis bodes well, though manufacturing clearances and continuity will also be closely watched.
Going by recent events, Lupin Ltd. can count on new product launches in major markets like the US and EU to aid its FY2021 performance even while the outlook on production remains mixed with benefits of regulatory approvals for some plants shaved to some extent by overall operational difficulties due to the COVID-19 related ongoing lockdown in India.
The company secured tentative approval from the US Food and Drug Administration (FDA) for a generic version of Sunovion Pharmaceuticals Inc
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
An ‘historic economic prosperity deal’ does not include the sector.
The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.
